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The promyelocytic cell line, HL-60, has been extensively 
studied for its ability to terminally differentiate in res¬ 
ponse to various chemical inducers, including, but not li¬ 
mited to, DMSO and retinoic acid. It has also been noted 
that the myc oncogene is amplified and highly expressed in 
these cells. Furthermore, differentiation in this line, as 
well as in several other cell lines, is accompanied by a 
marked decline in myc expression, leading to the hypothesis 
that this decline is mechanistically important for differen¬ 
tiation to occur. To probe this phenomenon more closely and 
to test this hypothesis I isolated an HL-60 mutant that no 
longer responded to DMSO induced differentiation and measured 
myc expression in these cells following exposure to DMSO, 
retinoic acid, or a combination of the two. I show that such 
a mutant is also partially cross resistant to retinoic acid 
induced differentiation, that the myc gene locus is not 
rearranged or changed in amplification status, and that a 
decline in myc expression can be associated with an undif¬ 
ferentiated, replicating phenotype. 
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The HL-60 cell line was originally isolated from a 
patient with acute promyelocytic leukemia (1,2). It has been 
shown that a variety of agents can induce these cells to 
differentiate along either the granulocytic, monocytic, or 
even eosinophilic pathways (3-15). The morphological matura¬ 
tion is accompanied by numerous functional and cytochemical 
changes, including the acquisition of the ability to reduce 
NET, an assay for the ability of phagocytic cells to generate 
an oxidative burst (4). Although most of these changes 
approximate the characteristics of normal granulocytes or 
macrophages, it has been pointed out that there are signifi¬ 
cant differences (16,17). Of particular note is the ability 
of uninduced HL-60 cells to divide continuously in culture, 
an unusual characteristic even of most leukemias, and their 
grossly abnormal karyotype (2), which does not correspond to 
any commonly recognized association between karyotype and 
malignancy (18). 
Yet, like normal terminally differentiated cells, in¬ 
duced HL-60 cells have a finite lifetime and cannot be main¬ 
tained in culture or cloned (19). It is for this reason, 
that they are believed to be a good model system to investi¬ 
gate differentiation mechanisms and to explore differentia¬ 
tion induction as a possible therapeutic modality. 
Oncogenes were first isolated from transforming retro¬ 
viruses (20) and subsequently from NIH3T3 cells transfected 
% 
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with tumor DNA (21). They have since been identified in 
normal cells and their elevated expression or mutated forms 
identified in numerous human and animal malignancies (22-26). 
Oncogenes are thought to be involved in regulating growth and 
replication. In fact, several have been shown to be growth 
factors or growth factor receptors (27-32). The protein 
product of others, such as the myc oncogene, have also been 
shown to reside in the nucleus and to bind double stranded 
DNA (33). Since a cardinal manifestation of a malignant cell 
is an undifferentiated phenotype, a role for some oncogenes 
in maintaining such a state or in initiating the differen¬ 
tiated state was soon hypothesized and explored. One of the 
first such investigations used the HL-60 leukemia and showed 
that during differentiation the RNA expression of the myc 
oncogene was greatly reduced (34). It had already been shown 
that the myc gene locus is amplified in these cells (35,36). 
Subsequent work showed changes in other oncogenes, including 
a similar decline in the expression of another nuclear onco¬ 
gene, myb (37), and extended these observations to other 
differentiating cell lines (38-40). 
In further studies, the kinetics of the decline in myc 
expression were more carefully defined (19,41), demonstrating 
that they are mostly due to a specific decline in the myc 
transcription rate (42). The decrease in expression is also 
accompanied by a slight change in SI nuclease sensitive sites 
of the myc gene (43). Finally, constitutive expression of 
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myc in a mouse erythroleukemia line inhibited DMSO or HMBA 
induced differentiation (44-46), but transgenic mice with a 
similarily activated myc locus developed normally (47,48). 
Thus, although it seemed that high myc levels were sufficient 
to maintain the undifferentiated replicating phenotype, there 
was no direct information as to whether high levels of ex¬ 
pression were necessary. 
To analyze the importance of myc expression to the 
differentiation process, I developed a mutant HL-60 line 
which no longer responded to DMSO induced differentiation and 
measured the effects of DMSO exposure on myc expression. 
Several other investigators have reported isolating DMSO 
resistant HL-60 cells (49-52). One report documented cross¬ 
resistance to several other inducers, as well as a reduction 
in the myc gene copy number (51). Accompaning changes in the 
expression of several cell membrane proteins were also noted, 
but myc RNA expression was not measured (53). Another report 
showed a slight decline in myc expression in a DMSO resistant 
mutant, but the decrease was only 2-fold and only dot-blots 
were used to document the finding (52). Here I report a 
marked decline in myc RNA expression following DMSO exposure 






HL-60 cells were originally obtained from Dr. Robert C. 
Gallo of the National Cancer Institute (1) and stock cultures 
were maintained and stored at our facilities. Cells were 
grown in RPMI 1640 supplemented with 10% heat inactivated 
fetal bovine serum, 100 units/ml penicillin, and 100 ug 
streptomycin at 37°C in a 5% CO2 humidified incubator. They 
were kept in exponential phase by splitting every 2-3 days 
and were periodically tested to insure freedom from mycoplas¬ 
ma infection. Every set of experiments was conducted by 
growing a sufficient number of cells such that all treatments 
and time points were begun concurrently and with the same set 
of seed cultures. All media were prewarmed to 37°C. 
The mutant cells were isolated as described in the 
Results section and were maintained in the manner described 
above except that the medium was also supplemented with 1.2% 
DMSO. Before beginning an experiment, cells were washed in 
drug-free medium and passaged once in drug-free medium before 
resuspending in the appropriate treatment flasks. All cell 
counts were obtained on a Coulter model ZBI particle counter. 
NBT TEST AND STAINING 
To measure differentiation, cells were cytospun onto 
acid-washed slides, fixed, and stained for morphological 
- 
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evaluation by a rapid staining solution (Canko Quik Stain II) 
that approximates the Wright-Giemsa stain. The NBT test was 
6 
conducted as previously described (4). One x 10 cells were 
resuspended in 0.5 ml of medium and 0.5 ml of 0.2% NBT (made 
up in sterile PBS protected from light, and stored at 5°C). 
TPA (from a 1 mM stock solution made up in DMSO, protected 
from light, and stored at -20°C) was added to a final concen¬ 
tration of 0.1 uM and the suspension incubated at 37°C for 20 
min. The reaction was stopped by placing the solution on 
ice, the cells were collected by centrifugation, resuspended 
in a minimal amount of medium, and the percentage of cells 
containing black formazan particles was measured using a 
standard counting chamber. All cell counts (for both morpho¬ 
logy and NBT reduction) were done blindly, in at least dupli¬ 
cate, and at least 200 cells were counted each time. 
NORTHERN ANALYSIS 
RNA was isolated by the guanidine thiocyanate method 
(54) and analysed by Northern blotting (55,56). Briefly, 
cells collected by centrifugation were washed in ice-cold 
PBS, and resuspended in 0.7 ml of 4 M guanidine thiocyanate 
in 25 mM sodium citrate with 0.1 M 2-mercaptoethanol 
(pH = 7.0). Cells were immediately vortexed and 0.5% Sarko- 
syl was added to complete the cellular disruption. This 
mixture was layered over 4 ml of 5.7 M CsCl in 25 mM sodium 
citrate (pH * 5.0) and centrifuged at 32K RPM in a Beckman 
, 
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SW-40 rotor for 18 h at 20°C. The RNA pellet was resuspended 
in sterile water and reprecipitated. The final RNA pellet 
was resuspended in TE7.5 and quantitated spectrophotometric- 
ally by A260. 
Ten ug of RNA was heat-denatured in 50% formamide and 6% 
formaldehyde and loaded onto a 1.2% agarose formaldehyde gel. 
After electrophoresis in lx MOPS, the 18S and 28S bands were 
visualized by acridine orange staining and the RNA trans¬ 
ferred to nitrocellulose with 5x SSC. 
The baked filters were prehybridized in a buffer con¬ 
taining 50% formamide and 10% dextran sulfate at 42°C for 2 
to 12 hr and then hybridized in the same solution for ap¬ 
proximately 24 hr at 42°C. Blots were rinsed in 2x SSC with 
0.5% SDS at room temperature, washed for 15 min in 2x SSC 
with 0.5% SDS at room temperature, washed for 20 min in lx 
SSC with 0.1% SDS at 42°C, and finally washed for 30 min in 
0.5x SSC with 0.1% SDS at 65°C. The blots were exposed to 
Kodak XRP film for 24 to 48 hours at -70°C. 
CYTODOT ANALYSIS 
Cytodot analysis was accomplished by a modification of a 
published technique (57) that was arrived at after systematic 
6 
analysis (see Figure 1). Two x 10 cells were washed twice 
in ice-cold PBS and resuspended in 45 ul of TE7.0 and 1000 
units of RNAsin. Five ul of 5% NP40 were added and the 




FIGURE 1: Cytodot probed with v-myc♦ Lane 2 cells treated 
with NP40, RNasin, and Centrifugation as described in Meth¬ 
ods, other lanes had the following changes. 1,10: no RNAse 
inhibitors added; 3,5,7,9: vanadyl nucleoside analogs replace 
RNAsin; 4-7,10: phenol/c’nloroform extraction of supernatant 
added; 6-10: proteinase K treatment of supernatant added; 11: 
same as 6, but RNAse added at end. 
CYTODOT PROTOCOL DEVELOPMENT 
I 23456 789 10 II 
I x I06 • • • 
5 x I05 • • • 
2.5x I05 • • • 
I.2xl05 
6.2x I04 




were added and the mixture was incubated on ice for a further 
5 minutes. The nuclei were collected by centrifugation and 
50 ul of the resulting suspension were added to 30 ul of 
20x SSC. The RNA was denatured with 7% formaldahyde at 60°C 
for 20 min and the amount of solution representing 1 x 10^ 
cells was placed on Gene-Screen with a Minifold blotting 
apparatus. Dilutions (1:2) were made with 15x SSC. The 
filters were baked and blotted as above. 
SOUTHERN ANALYSIS 
DNA was isolated from cells by a phenol/chloroform me¬ 
thod and analyzed by Southern blotting (56,58). Briefly, 
cells were collected by centrifugation, washed in ice-cold 
PBS, resuspended in TE8.0, and lysed with 10 volumes of a 
0.5 M EDTA, 0.5% Sarkosyl, and 100 ug/ul proteinase K 
solution at 50°C. The nucleic acids were extracted by re¬ 
peated phenol, phenol/chloroform, and chloroform extrac¬ 
tions and the solution dialyzed against TE8.0. RNA was 
removed by treating the solution with DNAse-free RNAse fol¬ 
lowed by repeated phenol/chloroform extractions. After a 
second dialysis against TE8.0, the DNA was concentrated by 
reprecipitation, and quantitated spectrophotometrically by 
A260. Agarose gel electrophoresis showed that all of the DNA 
so isolated was greater than 23kb. 
Approximately 12 ug of DNA were cut by restriction 
enzymes (56), the fragments separated on a 1.2% agarose gel, 
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and then transferred to nitrocellulose. Prehybridization, 
hybridization, and washing were as for the Northern analysis. 
PROBES 
For Southern blots, a v-myc probe (59) provided by Dr. 
Mark Carmen was used. For Northern blots, a murine c-myc 
probe (60,61) and a human N-ras probe isolated from HL-60 
cells (62), both of which were received from the American 
Type Culture Collection, were used. Probes were isolated 
from coli using standard procedures (56). 
g 
All probes were labeled to approximately 9 x 10 cpm/ug 
by an oligonucleotide labeling technique (63). Briefly, 
denatured probe was incubated with oligonucleotides, dATP, 
32 
dGTP, dTTP, P-dCTP, and the Klenow fragment of bacterial 
DNA synthetase. Free nucleotides were separated from the 
labeled probe by passage over a G-50 column. 
DENSITOMETRY 
Radioautographs were densitometrically scanned using a 
Zeineh soft laser scanning densitometer equipped with an 
Apple computer which was used for data analyses. 
CHEMICALS AND SOLUTIONS 
All chemicals used were of the highest grade available 
and supplied by standard laboratory suppliers. All solutions 
were sterilized in an autoclave before use. In addition, 
. 
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CELL ISOLATION AND CHARACTERIZATION 
Under the conditions employed parental HL-60 cells had a 
doubling time of about 36 hours and plateaued after 3 doub¬ 
lings. When treated with 1.2% DMSO or 1 uM RA, their growth 
was inhibited and they acquired a differentiated phenotype as 
assayed by the ability to reduce NBT (Figure 2). 
To create an HL-60 line resistant to DMSO induced dif¬ 
ferentiation, parental HL-60 cells were continuously main¬ 
tained in medium with serially increasing concentrations of 
DMSO until a culture resistant to 1.2% DMSO was created. 
This was successful in three instances. In each case the 
cells grew well in 1.2% DMSO (albeit somewhat more slowly 
than the parental line) without showing any ability to re¬ 
duce NBT. However, these resistant lines died when placed in 
drug-free medium, indicating a dependency on DMSO (*). Be¬ 
cause of the close resemblance to the growth characteristics 
of the parental line, one of these resistant lines, termed 
HL-60-DA, was selected for further study. 
Figure 3 shows the growth and differentiation of 
HL-60-DA cells in DMSO concentrations ranging from 1.2% to 
2.2%. The cells grew well in 1.2% to 1.6% DMSO; however, 
they demonstrated up to 20% NBT positivity at this latter 
concentration. As the DMSO was further increased, the cells 
grew less well and demonstrated greater NBT positivity. A 




FIGURE 2: HL-60 growth and differentiation (inset). Condi¬ 
tions and measurments are as described in Methods. Each 
point represents a separate flask and is the average of at 
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FIGURE 3: HL-60-DA dose response to DMSO. Culture conditions 
and measurments are as described in Methods. The accompaning 
tabular insert shows the percentage of cells capable of 
reducing NBT on the last day of culture. Cells treated with 




















DMSO concentration of 2.2% was toxic, as demonstrated by 
cellular vacuolation and debris after 3 days in culture. 
As mentioned above, it has been reported that myc ex 
pression decreases dramatically in parental HL-60 cells upon 
DMSO induced differentiation (34). Therefore, I assayed myc 
RNA levels in HL-60-DA cells during exponential growth, as 
well as during plateau phase. An RNA "dot blot" showed that 
myc expression in the mutant line was significantly lower 
than in the uninduced parental line and was approximately as 
low as in DMSO induced parental HL-60 cells (data not shown). 
These studies, however, were complicated by the necessity of 
continuously maintaining the mutant cell line in DMSO. It 
was impossible, therefore, to determine whether this decrease 
was a DMSO-induced effect or a permanent alteration. For 
this reason, I attempted to isolate a cell line that remained 
resistant to DMSO induced differentiation but was not depen¬ 
dent on it for growth. 
To this end, some HL-60-DA cells were placed in drug- 
free medium. In contrast to earlier results, after two 
passages a cell line developed that grew well both in the 
presence and absence of DMSO. This line, now termed HL-60- 
DAl, was maintained in drug-free medium. Figure 4 shows the 
growth and NBT positivity of HL-60-DA1 cells in 1.2% DMSO, in 
1 uM RA, and in drug free medium. This cell line grew 
slightly better in the medium with DMSO than in the drug-free 




FIGURE 4: Growth of HL-60-DA1 cells in presence of DMSO or RA 
Culture conditions and measurements are as described in Meth¬ 
ods. The accompaning tabular insert shows the percentage of 



















singly, the cells also grew well, and differentiated only 
partially (30% NBT positivity) when exposed to RA. Control 
HL-60 cells cultured at the same time and induced with either 
RA or DMSO showed the expected growth inhibition and greater 
than 75% NBT positivity at plateaued growth, thus demonstra¬ 
ting that the assays were functioning properly. Subsequent 
experiments demonstrated that the growth of HL-60-DA1 cells 
was inhibited and differentiation occurred, with the cells 
expressing greater than 75% NBT positivity, when they were 
placed in both 1.2% DMSO and luM RA (data not shown), thus 
proving that the resistance to differentiation was not abso¬ 
lute. 
The HL-60-DA1 cells maintained their mutant phenotype 
for approximately fifteen passages in drug-free medium and it 
was initially felt that this was a stable mutant. Unfortun¬ 
ately, as the cells continued to be passaged in drug-free 
media in preparation for measuring myc RNA expression, it was 
noted that they began to revert back to the parental pheno¬ 
type. For this reason, some of the early passage HL-60-DA1 
cells were removed from frozen storage and placed in medium 
supplemented with 1.2% DMSO to maintain the selective pres¬ 
sure. Unlike the parental line, the recovery of viable cells 
from the frozen stock of HL-60-DA1 cells was extremely low 
and estimated to be less than 1%. 
A viable culture was eventually created and these cells, 
now termed HL-60-DA2, were maintained in 1.2% DMSO until 
• 
22 
ready for study. Figure 5 shows their initial growth and 
differentiation. Although qualitatively similar to the ori¬ 
ginal HL-60-DAl cells, they do show some differences. They 
still grow well in drug free, DMSO treated, or RA treated 
media, but now show up to 50% NBT positivity with RA treat¬ 
ment. In addition, cells treated with both RA and DMSO also 
developed only 50% NBT positivity, although they did so more 
rapidly than those treated with RA alone. A control HL-60 
culture grown and assayed at the same time once again res¬ 
ponded as usual. To further characterize these cells, 
Wright-Giemsa stained samples from the cultures were examined 
for morphological changes (Figure 6). The cells in drug-free 
or DMSO treated media both matured slightly from predomin¬ 
antly promyelocytes to approximately 50% myelocytes. The 
drug-free cells seemed to mature somewhat more extensively, 
2 
but this was not statistically significant (p > 0.05 by X 
I 
analysis). Cells treated with both RA and DMSO differen¬ 
tiated so that a majority of the cells resembled metamyelo¬ 
cytes or bands. Unfortunately, the sample for the 8-day 
treatment with RA was lost thereby making analyses difficult. 
These findings confirmed the NBT results and correlated well 
with them, in so much as metamyelocytes are considered the 
earliest cells capable of expressing NBT positivity. 
Stock HL-60-DA2 cells were continuously maintained in 
1.2% DMSO for two months, at which time the confirmation of 




FIGURE 5: HL-60-DA2 growth and differentiation. Culture 



































FIGURE 6: Morphological differentiation of HL-60-DA2 cells 
Assay performed as described in Methods. All samples were 
blinded, at least 200 cells were counted, and the results 
represent the average of at least duplicate measurements. 
Error bars represent + one standard deviation or 5%, which 
ever is greater. 
HL-60-DA2 MORPHOLOGY 
CONTROL 1.2% DMSO 
m = promyelocytes E23 = myelocytes 
I I = metamyelocytes IM = hands 
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discussed below, was attempted. The experiment was repeated 
in the exact manner as before except that the cells were 
cultured in smaller flasks. Figure 7 shows their growth and 
NBT positivity and Figure 8 the morphological analysis. It 
is clear that the cellular characteristics had changed and 
thus they are now termed HL-60-DA3 cells. These cells grew 
well even in the presence of both RA and DMSO and expressed a 
maximum of 10% NBT positivity under those conditions. Mor¬ 
phology confirmed these results for the drug-free, the DMSO 
treated, and the RA treated cultures. The cultures treated 
with both RA and DMSO developed more metamyelocytes and bands 
than would be predicted from the NBT test but still not as 
many as the HL-60-DA2 cells (see Figure 6). Parental HL-60 
cells cultured and tested at the same time and with the same 
reagents once again behaved as expected. 
ANALYSIS OF THE MYC ONCOGENE 
RNA was isolated at various times from the cells des¬ 
cribed in Figures 5 and 6 and probed for the myc oncogene. 
Since it has been shown that N-ras RNA levels do not change 
with HL-60 differentiation (19), the blots were simultaneous¬ 
ly probed for this oncogene as a control. Figure 9 shows the 
Northern blots and Figure 10 the densitometric scanning re¬ 
sults. All bands are consistent with previously reported 




FIGURE 7: HL-60-DA3 growth and differentiation, 





































FIGURE 8: Morphological differentiation of HL-60-DA3 cells. 






























FIGURE 9: Northern analysis of total RNA isolated from HL-60- 
DA2 cells and probed with human N-ras and mouse c-myc. 
Twenty micrograms of total RNA were isolated, separated, and 
hybridized as described in Methods. Bands were labeled and 
confirmed by independent hybridizations. N-ras bands were 
more clearly visualized on the original autoradiograph and on 
overexposure of the film. 
MYC AND N-RAS RNA EXPRESSION 
HL-60 HL-60-DA2 
Control 1.2% DMSO Control 
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FIGURE 10: Densitometric measurements of Northern analysis 
from Figure 9. N-ras bands could not be scanned because of 
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exceptions attributable to loading variations, the RNA levels 
of N-ras remained relatively constant. Myc RNA levels, how¬ 
ever, varied dramatically. First of all, the untreated par¬ 
ental HL-60 cells consistently expressed high levels of myc 
which were dramatically reduced when the cells were induced 
to differentiate with DMSO. The 5 to 20-fold decrease in 
myc expression is consistent with previously published 
data (19,34). The untreated HL-60-DA2 cells showed even 
higher levels of myc RNA expression than the untreated paren¬ 
tal line. Given the difficulty of accurately scanning the 
high density bands in these experiments, it is not known if 
the modest decline over time seen in Figure 10 is signifi¬ 
cant. Treatment with DMSO, which in this line does not cause 
differentiation, once again caused a dramatic decrease in myc 
RNA. Treatment with RA, which causes moderate differenti¬ 
ation, induced similar changes. Treatment with RA and DMSO, 
which caused moderate differentiation at a faster rate than 
RA alone, produced a dramatic decline in myc RNA, similar to 
that seen in the differentiating parental line. 
To confirm these results, I attempted to repeat them 
using a cytodot method (57). Preliminary experiments showed 
that this was a feasible technique (see Methods). This 
method was chosen for its rapidity and convenience in ana¬ 
lyzing samples and time points. In addition, densitometric 
scanning was easier than with the Northern blots. The draw¬ 
backs include difficulty in controlling for nonspecific bin- 
/ 
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ding of the probe and, since RNA levels are expressed in 
units/cell rather than in units/ug of total RNA, difficulty 
in comparing the results to the earlier Northern blots. I 
attempted to circumvent the first by using the same stringent 
washing conditions as for the Northern analysis. The second 
difficulty, however, cannot be ameliorated, but it may be 
argued that the amount of myc per cell is the physiologically 
more important value. In addition to these drawbacks, and as 
described above, the characteristics of the HL-60 mutant 
changed in the interval between the experiments. 
Despite these problems the results were very similar. 
Figure 11 shows some of the representative blots and Figure 
12 the results from densitometric scanning. It should be 
first noted that the changes in myc RNA levels are not as 
dramatic as with the Northern blots. This finding is probab¬ 
ly due to the inherent high levels of nonspecific binding. 
Nevertheless, N-ras levels did not change with treatment or 
over time in the parental line, while a slight decline oc¬ 
curred over the course of the experiment in the mutant. This 
decline was consistent and equal for all of the four treat¬ 
ments. In addition, it was observed that the density of the 
N-ras dots in the mutant were higher than in the parental 
line. It is not known if this reflects a relatively higher 
concentration of that RNA species within the cell or simply 
an artifact. 




FIGURE 11: Representative cytodots probed with human N-ras or 
mouse c-myc. One xlO^ cells were treated, blotted onto gene- 
screen, and hybridized as described in Methods. Dilutions 
and probes used are indicated. 
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FIGURE 12: Densitometric measurements of cytodots represented 
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42 
significantly in HL-60 cells induced to differentiate with 
either DMSO or HA. The decrease was evident as early as 2 
hours and completed by 8 hours in the DMSO treated cells and 
by 24 hours in the RA treated ones. The untreated HL 60-DA3 
cells showed myc RNA levels that were consistantly twice 
those of the untreated parental line. When treated with 
DMSO, which did not induce differentiation, a dramatic early 
decrease in myc expression occurred which returned to inter¬ 
mediate levels afte 1 day. The change in myc RNA expression 
in RA treated HL-60-DA3 cells, that also did not differ¬ 
entiate, was somewhat different than in the results with the 
HL-60-DA2 cells. Myc RNA levels stayed high for several days 
and then decreased to intermediate levels when the plateau 
phase was reached. When HL-60-DA3 cells were treated with 
both RA and DMSO, which induced only minimal differentiation, 
the changes in myc were similar to those noted with the 
HL-60-DA2 cells. Thus, an early dramatic drop occurred with 
a slight reaccumulation at the time of plateau growth. A 
similar reaccumulation at the plateau phase also occurred in 
the DMSO treated cells. 
To analyze the myc genomic organization, DNA of the 
mutant line was analyzed by Southern blotting. Figure 13 
shows no difference between the HL-60 and the HL-60-DA2 cells 
indicating that no gross rearrangement or significant change 
in the amplification of the myc gene occurred in the mutant 




FIGURE 13: Southern analysis of the myc genome in HL-60 and 
HL-60-DA2 cells. Twelve micrograms of total DNA were diges¬ 
ted, separated and hybridized as described in Methods. Res¬ 
triction enzymes and molecular weight markers are as indi¬ 
cated. 
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their previously reported locations (44,59,65,66), except for 
the 4.0 kB EcoRl band and the high molecular weight band seen 
with BamHI digestion. The latter can be attributed to incom¬ 




A DMSO Selected Differentiation Mutant Exhibits Cross 
Resistance to Retinoic Acid 
An HL-60 mutant line that is resistant to DMSO and RA 
induced differentiation was developed and characterized. 
This line was then analysed for myc RNA expression in res¬ 
ponse to these agents. Although the line was created by 
selective pressure from constant DMSO exposure, it was found 
to also be resistant to RA induced differentiation, a finding 
previously reported for another DMSO resistant line (51). 
That the cells are indeed a differentiation mutant and not a 
mutant in the ability to respond to the NBT assay was shown 
by morphological analysis. 
The changing characteristics of this line are note¬ 
worthy. First, when no selective pressure was maintained the 
line reverted back to the parental phenotype; whereas, when 
the selective pressure was continuously maintained the line 
became even more cross-resistant to the RA. This in itself 
is not too surprising in so far as parental cells usually 
have a growth advantage under the standard culture conditions 
and will thus eventually dominate the culture. The mutants 
with the greatest resistance, on the other hand, will domi¬ 
nate when selection pressure is maintained. It is not im¬ 
mediately clear whether the phenomenon is due to inducible 
genetic material in a clonal line (such as homogeneously 
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staining chromosomal regions or double minute chromosomes) or 
to a heterogeneous cell population. It has been shown that 
the HL-60 line has a very aberrant karyotype that does con¬ 
tain double minutes, homogeneously staining regions, and am¬ 
plified genes (2,35,26,67,68). Genetic amplification that 
would then be lost in the abscence of selective pressure is 
thereby easily envisioned (69). However, given the large 
numbers of cells used and the previously reported karyotypic 
heterogeneity of the parental HL-60 cell line (2,67,68), it 
must be assumed that the mutant line is also a nonclonal and 
heterogeneous cell population. 
With this heterogeneity and the lack of knowledge re¬ 
garding the mechanism of differentiation produced by both 
DMSO and RA, it is difficult to dissect the exact mechanism 
by which the cells express resistance to differentiation. 
However, given the vastly different chemical structures and 
concentrations at which DMSO and RA are effective, it is not 
likely that their differentiation induction pathways are 
exactly the same. In fact, it has been postulated that RA 
exerts its effects through a specific RA binding protein 
(70,71), while DMSO may exert its effects through a nonspeci¬ 
fic membrane interaction (72). In addition, the original 
isolate of the mutant line described here responded partially 
to RA and responded well to combined treatment, thereby 
giving further support to the possible existence of multiple 
differentiation mechanisms. Nevertheless, because the final 
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outcome of all differentiation inductions are very similar, 
the biochemical events produced by each of these mediators 
must eventually intersect. Thus, since the line described 
here eventually became resistant to both agents, the mutation 
almost certainly involves one of these intersecting events. 
The Proliferating, Undifferentiated Phenotype Does Not 
Require Elevated myc Expression 
Once the resistant line was established, I attempted to 
use it to probe for the role of the myc oncogene in differen¬ 
tiation. The presumed heterogeneous cell cultures and the 
changing phenotype made rigorous analysis of the measurements 
impossible. The changes in both myc and N-ras RNA expres¬ 
sion in the parental line is well within the realms of pre¬ 
vious reports (19,34). The changes seen with the cytodot 
technique, as mentioned before, are not quite as dramatic as 
in other reports but, once again, this was attributed to the 
high nonspecific signal seen with this technique. Also, the 
kinetics of the decrease in myc were somewhat more rapid than 
in a previously published report (19). The reasons for this 
are unclear, but careful reading and analysis of published 
HL-60 growth curves and response to standard differentiation 
inducers from different laboratories shows that significant 
variation occurs despite comparable culture conditions. 
Thus, the different kinetics of the decline in myc RNA may 
simply be an example of divergent cell line evolution. 
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The results with the myc oncogene in the mutant HL-60 
line are at first glance confusing. However, some interest¬ 
ing conclusions can be made. The Northern gel of the 
HL-60-DA2 RNA clearly shows a marked decrease in myc RNA 
levels with both DMSO and RA treatment that is proportionally 
as great as that seen in the parental line when compared to 
the untreated control. Yet there is no or only limited 
differentiation. Thus, in this case, a decrease in myc RNA 
expression was not sufficient for differentiation to occur. 
Or looking at it in another way, high myc levels are not 
necessary to maintain the undifferentiated, proliferating, 
phenotype. It may be argued that it is not the relative 
amount of myc in a cell that is important but the absolute 
amount. The Northern blots leave this question open because 
myc RNA expression in both the RA and the DMSO treated cells, 
despite being relatively less than the untreated control, are 
still greater than the differentiating parental line. The 
myc RNA levels in the mutant cells treated with both RA and 
DMSO were decreased to the levels seen with DMSO treated 
parental cells, but they differentiate relatively well also. 
The cytodot analysis, however, showed that HL-60-DA3 
cells treated with both RA and DMSO have myc RNA levels that 
are at least as low as that seen in differentiating parental 
cells. In this case, though, they only differentiate to a 
limited extent. Thus, it seems that even an absolute decline 
in myc RNA levels is not sufficient to cause differentiation 
' 
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in this line. The cytodot methodology also confirms the 
consistantly high constant myc RNA levels in the untreated 
mutant cells. In addition, the cytodot analysis corroborated 
the decline in myc RNA, without cellular differentiation, 
that occurs with DMSO treatment. The very early decline in 
myc with subsequent reaccumulation is reminiscent of the 
changes seen in differentiating Friend leukemia cells (39). 
One report also claims elevated myc expression at 24-48 h in 
differentiating HL-60 cells (73). Since it was not looked 
for, it is not known if a similar biphasic change occurred in 
the cells used for the Northern blots. The high myc RNA 
levels seen with RA treatment of the HL-60-DA3 cells as well 
as the rise in myc RNA levels seen in the DMSO and in the RA 
plus DMSO treated cells at the plateau phase of growth was 
not consistent with earlier results and is incompletely un¬ 
de r stood. 
Finally, when attempting to define the importance of a 
putative mediator of a pathway, it is the function of the 
protein that is the physiologically important variable. Al¬ 
though myc protein and RNA levels have been correlated 
(74,80), until a good assay for myc protein function is 
developed, this limitation will remain. For now then, we 
will assume that a declining myc RNA level reflects a decline 
in the level and function of the myc protein. 
In general myc RNA levels decline dramatically with HL- 
60 differentiation (19,34,41), as well as with the differen- 
/ 
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tiation of several other cell lines (38,40). Also, recent 
work shows that constitutive expression of myc inhibits dif¬ 
ferentiation in mouse erythroleukemia cells (44-46). Ad¬ 
ditionally, the kinetics of the decline in myc RNA parallels 
the kinetics of the decline in the clonability and NBT 
positivity of HL-60 cells but not the kinetics of thymidine 
incorporation into DNA upon the induction of differentiation 
(19). Thus, the data suggest that a decline in myc expres¬ 
sion is necessary for differentiation. 
However, there are many experimental systems in which 
increased myc RNA levels are related to the entrance of the 
cells into a proliferative state (74-83). Thus, it seems 
that increased myc expression is associated with the proli¬ 
ferative state, and in fact may be directly involved in DNA 
replication (84). Another way of looking at the decrease in 
myc levels seen with differentiation, therefore, is that it 
may simply be a reflection of the concomitant loss of prolif¬ 
erative capacity. Although elevated myc levels are insuf¬ 
ficient to induce the replicative mode in some quiescent or 
differentiated cells (82), high myc levels could be suf¬ 
ficient to maintain the undifferentiated, proliferating 
phenotype (44-47). In this scenario, one could postulate 
that obligatory elevated myc expression occurs in all pro¬ 
liferating cells. Although this is certainly not true for 
all tumor cells (23,85), or even in all cells of a developing 
embryo (86), there has been little direct evidence for the 
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maintenance of the proliferating, undifferentiated phenotype 
in the face of declining levels of myc RNA. 
This study is the first to describe such a pattern. 
That is, a decline in myc expression is not correlated with 
either the differentiated phenotype or the inhibition of 
growth in the HL-60 differentiation mutant described here. 
If the decline in myc is seen as mechanistically an important 
step in the maturation process, the obvious conclusion is 
that a decrease in the expression of myc is not sufficient 
for differentiation or, alternatively, the lesion in the 
differentiation pathway of this mutant is distal to the point 
at which a decline in myc RNA is initiated. On the other 
hand, as suggested above, myc expression can be seen as 
mechanistically important in maintaining the proliferating, 
undifferentiated phenotype. In that case, despite other 
studies which have shown that high myc RNA expression is 
sufficient for maintaining the undifferentiated, prolifera¬ 
ting state (44-47), the conclusion of this study must be that 
it is not always necessary. 
NOTE ADDED IN PROOF: Since writing this, Ely et al (Cancer 
Res. 47, ?59~5-4600 ) have described a HL-60 mutant partially 
resistant to phorbol dibutyrate induced monocytic differen¬ 
tiation in which myc expression initially declines drama¬ 
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